Jan. 15 at 5:22 AM
$DTIL 1. Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences (Most Likely May 2026, EASL Congress, Barcelona) in 2026;
2. PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026;
3. Unaudited cash, cash equivalents, and restricted cash of approximately
$137 million as of December 31, 2025, anticipated to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028.
We may witness the very first cure for HBV using gene therapy
$NTLA $EDIT $CRSP by the end of this year! Wish us good luck! Go
$DTIL !!!
